loading
Schlusskurs vom Vortag:
$0.525
Offen:
$0.5171
24-Stunden-Volumen:
246.55K
Relative Volume:
0.14
Marktkapitalisierung:
$4.09M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-9.40%
1M Leistung:
-33.70%
6M Leistung:
-97.57%
1J Leistung:
-99.44%
1-Tages-Spanne:
Value
$0.5158
$0.535
1-Wochen-Bereich:
Value
$0.4901
$0.62
52-Wochen-Spanne:
Value
$0.4901
$109.00

Cero Therapeutics Holdings Inc Stock (CERO) Company Profile

Name
Firmenname
Cero Therapeutics Holdings Inc
Name
Telefon
650-407-2376
Name
Adresse
201 HASKINS WAY, SOUTH SAN FRANCISCO
Name
Mitarbeiter
8
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
CERO's Discussions on Twitter

Vergleichen Sie CERO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CERO
Cero Therapeutics Holdings Inc
0.53 3.26M 0 0 0 0.00
Biotechnology icon
ONC
Beigene Ltd Adr
241.43 27.03B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
436.00 112.64B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.335 40.86M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
588.34 64.17B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
75.06 6.07B 0 -153.72M -103.81M -2.00

Cero Therapeutics Holdings Inc Aktie (CERO) Neueste Nachrichten

pulisher
May 20, 2025

CERo Therapeutics (NASDAQ:CERO) Coverage Initiated by Analysts at Maxim Group - Defense World

May 20, 2025
pulisher
May 19, 2025

Maxim Group Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy Recommendation - Nasdaq

May 19, 2025
pulisher
May 19, 2025

Maxim Group sets Cero Therapeutics stock with $3 target By Investing.com - Investing.com Nigeria

May 19, 2025
pulisher
May 19, 2025

CERO Therapeutics (CERO) Receives 'Buy' Rating from Maxim Group | CERO Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Maxim Group sets Cero Therapeutics stock with $3 target - Investing.com

May 19, 2025
pulisher
May 19, 2025

CeroTherapeutics (CERO) Receives Buy Rating from Maxim Analyst | CERO Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Cero Therapeutics (CERO) Gains Buy Rating with Innovative T-Cell Therapy | CERO Stock News - GuruFocus

May 19, 2025
pulisher
May 16, 2025

CERo Therapeutics (NASDAQ:CERO) Stock Price Up 1.5% – Here’s What Happened - Defense World

May 16, 2025
pulisher
May 15, 2025

CERO THERAPEUTICS HOLDINGS, INC. SEC 10-Q Report - TradingView

May 15, 2025
pulisher
May 14, 2025

Pre-market Movers: LUCY, ALUR, PLRZ, AXDX... - RTTNews

May 14, 2025
pulisher
May 12, 2025

CERo Therapeutics regains Nasdaq compliance - MSN

May 12, 2025
pulisher
May 08, 2025

CERo Therapeutics Regains Nasdaq Compliance with Stockholder Equity - TipRanks

May 08, 2025
pulisher
May 08, 2025

CERo Therapeutics regains Nasdaq compliance, eyes trials - Investing.com Australia

May 08, 2025
pulisher
May 08, 2025

CERo Therapeutics regains Nasdaq compliance, eyes trials By Investing.com - Investing.com South Africa

May 08, 2025
pulisher
May 08, 2025

CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1) - The Manila Times

May 08, 2025
pulisher
May 08, 2025

CERo Therapeutics Regains Compliance with Nasdaq Listing Rule Following Successful Fundraising Efforts - Nasdaq

May 08, 2025
pulisher
May 03, 2025

CERo Therapeutics Holdings Inc (NASDAQ: CERO): Blank Check On Growth? - Stocksregister

May 03, 2025
pulisher
May 02, 2025

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity - ADVFN

May 02, 2025
pulisher
Apr 30, 2025

CERo Therapeutics begins phase 1 trial for leukemia treatment - Investing.com Australia

Apr 30, 2025
pulisher
Apr 30, 2025

CERo Therapeutics Initiates Phase 1 Clinical Trial for CER-1236 at TriStar Centennial Medical Center to Treat Acute Myeloid Leukemia - Nasdaq

Apr 30, 2025
pulisher
Apr 30, 2025

Cero Therapeutics Announces Tristar Centennial Medical Center As A Clinical Trial Site For Its Phase 1 Clinical Trial Of Cer-1236 In Acute Myeloid Leukemia - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

CERo Therapeutics Holdings, Inc. Announces TriStar - GlobeNewswire

Apr 30, 2025
pulisher
Apr 30, 2025

Leading Cancer Center to Test Revolutionary AML Treatment: CERo's Novel T Cell Therapy Enters Clinical Trial - Stock Titan

Apr 30, 2025
pulisher
Apr 28, 2025

CERo Therapeutics Holdings Inc (CERO) Stock: A Year of Market Movement, Down and Up - investchronicle.com

Apr 28, 2025
pulisher
Apr 28, 2025

CERo Therapeutics announces up to $8M Series D financing; shares up - MSN

Apr 28, 2025
pulisher
Apr 25, 2025

CERo Therapeutics Holdings Inc [CERO] is -81.50% lower this YTD. Is it still time to buy? - dbtnews.com

Apr 25, 2025
pulisher
Apr 25, 2025

Market cap of Crown LNG Holdings Limited [CGBS] reaches 59.64M – now what? - dbtnews.com

Apr 25, 2025
pulisher
Apr 25, 2025

New Providence Acquisition Corp III [NPACU] Stock trading around $10.02 per share: What’s Next? - dbtnews.com

Apr 25, 2025
pulisher
Apr 25, 2025

A company insider recently sold 50,896 shares of OppFi Inc [OPFI]. Should You Sale? - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

CERo Therapeutics Holdings Inc [CERO] Records 50-Day SMA of $1.1308 - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

CERo Therapeutics Holdings, Inc. to Present Poster on Lead - GlobeNewswire

Apr 25, 2025
pulisher
Apr 25, 2025

Breakthrough Leukemia Treatment: CERo's First-in-Human Trial Results Revealed at ASCO 2025 - Stock Titan

Apr 25, 2025
pulisher
Apr 25, 2025

Holdings of CERo Therapeutics Holdings Inc (CERO) are aligned with the stars - Sete News

Apr 25, 2025
pulisher
Apr 25, 2025

CERo Therapeutics Holdings Inc’s Market Journey: Closing Strong at 1.11, Up 38.85 - DWinneX

Apr 25, 2025
pulisher
Apr 25, 2025

Market Momentum: Haoxin Holdings Ltd (HXHX) Registers a 16.47 Increase, Closing at 1.98 - DWinneX

Apr 25, 2025
pulisher
Apr 25, 2025

CERo Therapeutics (NASDAQ:CERO) Upgraded at D Boral Capital - Defense World

Apr 25, 2025
pulisher
Apr 24, 2025

CERo Therapeutics begins Phase 1 trial for AML treatment By Investing.com - Investing.com South Africa

Apr 24, 2025
pulisher
Apr 24, 2025

Gold Gains 1%; Bristol Myers Squibb Posts Upbeat ResultsASGN (NYSE:ASGN), Bristol-Myers Squibb (NYSE:BMY) - Benzinga

Apr 24, 2025
pulisher
Apr 24, 2025

Dow Jumps Over 200 Points; PepsiCo Cuts Earnings Outlook - Benzinga

Apr 24, 2025
pulisher
Apr 24, 2025

CERo Therapeutics Holdings Inc (CERO)’s stock price range in the last year - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

CERo Therapeutics begins Phase 1 trial for AML treatment - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia - The Manila Times

Apr 24, 2025
pulisher
Apr 24, 2025

CERo Therapeutics Announces Clinical Trial Partnership with Sarah Cannon Research Institute for Phase 1 Trial of CER-1236 in Acute Myeloid Leukemia - Nasdaq

Apr 24, 2025
pulisher
Apr 24, 2025

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon - GlobeNewswire

Apr 24, 2025
pulisher
Apr 24, 2025

Major Blood Cancer Center Joins CERo's Novel AML Treatment Trial, June Dosing Planned - Stock Titan

Apr 24, 2025
pulisher
Apr 23, 2025

CERo Therapeutics (NASDAQ:CERO) Coverage Initiated by Analysts at D. Boral Capital - Defense World

Apr 23, 2025
pulisher
Apr 22, 2025

Boral Capital sets Cero Therapeutics stock with Buy rating - Investing.com Australia

Apr 22, 2025
pulisher
Apr 22, 2025

CERo Therapeutics secures $8 million in funding for cancer therapy By Investing.com - Investing.com South Africa

Apr 22, 2025
pulisher
Apr 22, 2025

What Are You Thinking About Investing In CERo Therapeutics Holdings Inc (NASDAQ: CERO) Stock? - Stocksregister

Apr 22, 2025
pulisher
Apr 22, 2025

CERo Therapeutics Raises Up To $8 Mln To Advance T Cell Therapy Programs - Nasdaq

Apr 22, 2025
pulisher
Apr 22, 2025

D. Boral Capital Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy Recommendation - Nasdaq

Apr 22, 2025

Finanzdaten der Cero Therapeutics Holdings Inc-Aktie (CERO)

Es liegen keine Finanzdaten für Cero Therapeutics Holdings Inc (CERO) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Cero Therapeutics Holdings Inc-Aktie (CERO) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
YK Bioventures Opportunities G
10% Owner
Dec 13 '24
Sale
0.06
2,998,908
179,934
13,005,169
YK Bioventures Opportunities G
10% Owner
Dec 12 '24
Sale
0.07
1,614,541
113,018
16,004,077
YK Bioventures Opportunities G
10% Owner
Dec 11 '24
Sale
0.08
1,343,801
107,504
17,618,618
YK Bioventures Opportunities G
10% Owner
Dec 06 '24
Sale
0.12
1,236,874
148,425
21,383,909
YK Bioventures Opportunities G
10% Owner
Dec 10 '24
Sale
0.09
1,570,947
141,385
18,962,419
YK Bioventures Opportunities G
10% Owner
Dec 09 '24
Sale
0.11
850,543
93,560
20,533,366
SLOAN STUART M
10% Owner
Sep 25 '24
Sale
0.10
532,486
55,538
21,067,956
YK Bioventures Opportunities G
10% Owner
Oct 10 '24
Sale
0.10
3,250,000
325,000
22,620,783
$1.15
price down icon 17.27%
$31.32
price down icon 3.63%
$587.61
price up icon 1.06%
$289.96
price up icon 0.33%
$4.25
price up icon 0.48%
$75.06
price up icon 3.26%
Kapitalisierung:     |  Volumen (24h):